Clinical Trial Update: An Open-Label Study to Evaluate the Intraduodenal Delivery of Enzymes From Administration of VIOKASE16 in Exocrine Pancreatic Insufficiency (EPI) [Phase 2]

View source ↗

Summary

An open-label Phase 2 trial evaluated intraduodenal delivery of enzymes from VIOKASE16 in exocrine pancreatic insufficiency and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Exocrine Pancreatic Insufficiency

Drugs mentioned

• VIOKASE16 (pancreatic enzyme replacement therapy)

Snippet

Sponsor: Axcan Pharma | Conditions: Exocrine Pancreatic Insufficiency | Phase 2 | Status: COMPLETED